AU Patent

AU2023232162A1 — Compositions and methods for expressing therapeutics

Assigned to Avirmax Biopharma Inc · Expires 2024-10-24 · 2y expired

What this patent protects

Described herein are compositions and method for expressing therapeutics. The compositions comprise engineered polypeptides comprising a natriuretic peptide connected to an antibody or fragment thereof. AAV vectors encoding said engineered polypeptides are also disclosed, and the…

USPTO Abstract

Described herein are compositions and method for expressing therapeutics. The compositions comprise engineered polypeptides comprising a natriuretic peptide connected to an antibody or fragment thereof. AAV vectors encoding said engineered polypeptides are also disclosed, and therapeutic use thereof to treat diseases such as glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number: AU2023232162A1
Jurisdiction: AU
Classification: —
Expires: 2024-10-24
Drug substance claim: No
Drug product claim: No
Assignee: Avirmax Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.